Oritavancin: Difference between revisions
From IDWiki
(Imported from text file) |
No edit summary |
||
| Line 1: | Line 1: | ||
| − | = Oritavancin = |
||
| − | |||
| − | == Classification == |
||
| − | |||
* Semisynthetic lipoglycopeptide antibiotic with very long half-life |
* Semisynthetic lipoglycopeptide antibiotic with very long half-life |
||
| Line 17: | Line 13: | ||
* Not required |
* Not required |
||
| + | [[Category:Antibiotics]] |
||
| − | == Adverse Events == |
||
Revision as of 07:51, 16 August 2019
- Semisynthetic lipoglycopeptide antibiotic with very long half-life
Indications
- MRSA skin and soft tissue infections
Dosing
- IV once a week, long-acting
Renal Dosing
- Not required
